Advertisement
U.S. markets closed
S&P Futures
5,887.75 -4.75 (-0.08%) Dow Futures
43,048.00 -121.00 (-0.28%) Nasdaq Futures
20,517.50 -24.50 (-0.12%) Russell 2000 Futures
2,246.60 +0.40 (+0.02%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,760.30 +0.50 (+0.02%)
Prime Medicine, Inc. (PRME)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
| Previous Close | 4.3700 |
| Open | 4.3100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.0680 - 4.4800 |
| 52 Week Range | 3.2800 - 9.8600 |
| Volume | |
| Avg. Volume | 1,381,820 |
| Market Cap | 535.338M |
| Beta (5Y Monthly) | 2.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.80 |
Motley FoolWhy I Keep Buying These 14 Incredible Growth Stocks
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.
GlobeNewswirePrime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
-- On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.